Johnson & Johnson (JNJ): What You Should Know

Page 1 of 2

Johnson & Johnson (NYSE:JNJ)“Other guys read Playboy. I read annual reports.”

– Warren Buffett

I’m not quite as fanatical as Warren, but I do enjoy digging into a company’s annual report (called a 10-K) to learn something new. Especially for companies I own.

Over the next few weeks, I’ll be reading the 10-Ks of all the companies I own shares in, first page to the last. This week: Johnson & Johnson (NYSE:JNJ).

Here are five things I learned from J&J’s annual report (which you can read here).

1. A lot of the company’s slowing revenue growth doesn’t have to do with sales, but currency
Johnson & Johnson (NYSE:JNJ)‘s sales growth is tepid at best. Revenue growth has averaged 2.3% per year over the last five years, or about equal to the U.S. inflation rate.

But take a look at this table:

Sales Increase / (Decrease) Due to: 2012
Volume 5.7%
Price 0.4%
Currency (2.7%)
Total 3.4%

Johnson & Johnson’s ability to sell stuff actually grew nicely in 2012. And it managed to do so with slightly higher prices.

What took down revenue growth were currency fluctuations.

Consider how big currency issues were in Europe alone (emphasis mine): “Sales in Europe experienced a decline of 1.1% as compared to the prior year, including operational growth of 5.8% offset by a negative currency impact of 6.9%.”

The irony here is that many investors admired companies like Johnson & Johnson (NYSE:JNJ) for their exposure to international sales, which was seen as a hedge against a weakening dollar. But now that the dollar is gaining value against a basket of global currencies, international exposure becomes a drag, net of currency hedges. Be careful what you wish for.

2. Forget about runaway inflation of medical costs
Everyone knows health care prices ballooned over the last decade. Companies operating in the health care universe, therefore, were said to benefit from the other side of that trend with above-average pricing power and revenue growth.

But that hasn’t been the case for Johnson & Johnson (NYSE:JNJ)’s health care units. Take this paragraph (emphasis mine):

The Company is aware that its products are used in an environment where, for more than a decade, policymakers, consumers and businesses have expressed concerns about the rising cost of health care. In response to these concerns, the Company has a long-standing policy of pricing products responsibly. For the period 2002 - 2012, in the United States, the weighted average compound annual growth rate of the Company’s net price increases for health care products (prescription and over-the-counter drugs, hospital and professional products) was below the U.S. Consumer Price Index (CPI).

3. Don’t wait around for foreign profits to come home
When a company earns profits overseas, the act of bringing that cash back to the United States to pay dividends or fund share buybacks can create a big tax bill. Called the “repatriation tax,” companies typically owe the difference between the tax rate they paid on earnings overseas and the U.S.’s 35% tax rate.

Many companies opt to hoard cash overseas, anticipating a repatriation-tax holiday in the future that will let them bring cash home without spiking their tax liabilities.

But don’t wait around for Johnson & Johnson (NYSE:JNJ) to bring foreign profits home. It seems content reinvesting the majority of its foreign profits into foreign operations (emphasis mine):

At December 30, 2012 and January 1, 2012, the cumulative amounts of undistributed international earnings were approximately $49.0 billion and $41.6 billion, respectively. At December 30, 2012 and January 1, 2012, the Company’s foreign subsidiaries held balances of cash and cash equivalents in the amounts of $14.8 billion and $24.5 billion, respectively. The Company has not provided deferred taxes on the undistributed earnings from certain international subsidiaries where the earnings are considered to be permanently reinvested. The Company intends to continue to reinvest these earnings in international operations.

Page 1 of 2
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Largest Pharmaceutical Companies In the World

The 10 Most Expensive Android Apps

The 9 Most Expensive Designer Bags in the World

The 7 Most Expensive Real Estate in the World

The 10 Most Expensive eBay Items Ever Sold

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!